CHAPTER ONE

THE DRUG DEVELOPMENT PIPELINE

• Drugs in Worldwide Clinical Development
• New Drug Approvals
• Distribution of Global Drug Pipeline by Research Phase
• Worldwide Active R&D Projects in Development
• Distribution of Active Projects in Clinical Phases Only
• Trends in Active Projects in Development Worldwide by Phase
• Comparing Study Size by Phase
• Distribution of Global Pipeline by Molecule Type
• The Biosimilars Clinical Pipeline by Phase
• Biologic Medicines in Development
• Potential First-in-Class Medicines in the Pipeline
• Number of Companies with Active Clinical Projects Worldwide
• Top Five Largest Pharmaceutical Company Pipelines
• Most Active Clinical Pipelines
• Drugs in Preclinical Testing
• New Clinical Trials Started: Number of Trials Initiated
• Worldwide Clinical Trial Initiations
• Worldwide Clinical Trials Volume: Active Phase I-III Trials
• Percent of Clinical Trials Initiated Outside the US
• Distribution of Active Clinical Trials

• Active Phase I Clinical Trials Worldwide
• Active Phase II Clinical Trials Worldwide
• Active Phase III Clinical Trials Worldwide
• Active Phase IV Clinical Trials Worldwide
• Distribution of Global R&D Projects by Therapeutic Area
• Drugs in Clinical Development by Therapeutic Area
• Top Five Most Active Therapeutic Areas in Clinical Testing
• Therapeutic Area Growth
• Distribution of Active Global Phase I Projects by Therapeutic Area
• Global Compounds in R&D by Therapeutic Area: Top Five
• Global Compounds in R&D by Therapeutic Area: Next Five
• Worldwide R&D Pipeline by Therapeutic Area
• Worldwide R&D Pipeline by Therapeutic Area
• Worldwide R&D Pipeline by Therapeutic Area
• Worldwide R&D Pipeline by Therapeutic Area
• Worldwide R&D Pipeline by Therapeutic Area
• Projects in Development by Therapeutic Area
• Projects in Development by Therapeutic Area
• Projects in Development by Therapeutic Area
• Oncology Drugs in the R&D Pipeline
• Number of Vaccine Drugs in Development
CHAPTER ONE
THE DRUG DEVELOPMENT PIPELINE

• An Expanding Vaccine Pipeline
• Primarily Phase I and II Growth in the Vaccines Development Pipeline
• Top Five Fastest Growing Therapeutic Areas by Prescription Drug Sales

• Distribution of Active Global R&D Projects by Phase
• Active Projects in Global Phase I Clinical Trials
CHAPTER ONE
THE DRUG DEVELOPMENT PIPELINE

- Drugs in Worldwide Clinical Development
- New Drug Approvals
- Distribution of Global Drug Pipeline by Research Phase
- Worldwide Active R&D Projects in Development
- Distribution of Active Projects in Clinical Phases Only
- Trends in Active Projects in Development Worldwide by Phase
- Comparing Study Size by Phase
- Distribution of Global Pipeline by Molecule Type
- The Biosimilars Clinical Pipeline by Phase
- Biologic Medicines in Development
- Potential First-in-Class Medicines in the Pipeline
- Number of Companies with Active Clinical Projects Worldwide
- Top Five Largest Pharmaceutical Company Pipelines
- Most Active Clinical Pipelines
- Drugs in Preclinical Testing
- New Clinical Trials Started Number of Trials Initiated
- Worldwide Clinical Trial Initiations
- Worldwide Clinical Trials Volume Active Phase I-III Trials
- Percent of Clinical Trials Initiated Outside the US
- Distribution of Active Clinical Trials
- Active Phase I Clinical Trials Worldwide
- Active Phase II Clinical Trials Worldwide
- Active Phase III Clinical Trials Worldwide
- Active Phase IV Clinical Trials Worldwide
- Distribution of Global R&D Projects by Therapeutic Area
- Drugs in Clinical Development by Therapeutic Area
- Top Five Most Active Therapeutic Areas in Clinical Testing
- Therapeutic Area Growth
- Distribution of Active Global Phase I Projects by Therapeutic Area
- Global Compounds in R&D by Therapeutic Area: Top Five
- Global Compounds in R&D by Therapeutic Area: Next Five
- Worldwide R&D Pipeline by Therapeutic Area
- Worldwide R&D Pipeline by Therapeutic Area
- Worldwide R&D Pipeline by Therapeutic Area
- Worldwide R&D Pipeline by Therapeutic Area
- Projects in Development by Therapeutic Area
- Projects in Development by Therapeutic Area
- Projects in Development by Therapeutic Area
- Oncology Drugs in the R&D Pipeline
- Number of Vaccine Drugs in Development
CHAPTER ONE
THE DRUG DEVELOPMENT PIPELINE

- An Expanding Vaccine Pipeline
- Primarily Phase I and II Growth in the Vaccines Development Pipeline
- Top Five Fastest Growing Therapeutic Areas by Prescription Drug Sales
- Distribution of Active Global R&D Projects by Phase
- Active Projects in Global Phase I Clinical Trials
CHAPTER TWO
DRUG DEVELOPMENT PERFORMANCE

- Cycle Time
- Overall Drug Development Timelines During Three Decades
- The Fastest Drug Developers
- Comparing the Fastest and the Slowest Companies (2000-2013)
- Wide Variability in Clinical and NDA Approval Duration
- Traditional Development Duration
- Drug Development Duration
- Clinical Approval Times for Drugs and Biopharmaceuticals
- Clinical and Approval Times
- Cycle Time Acceleration Targets
- Traditional Clinical Development Scope, Purpose and Duration
- Success Rates
- Phase Transition Probabilities for All Drugs
- Success Rate Variation by Molecule Size
- NCE Approval Success Rates by Therapeutic Class
- Success Rates by Therapeutic Area and Phase
- Success Rates in Oncology
- Average Cycle Time from Site Initiation to First Patient Randomized
- Are Global Trials Really Faster?
- Total Approval Phase for Drugs with NDAs or BLAs Submitted FY1996-2006
- Mean US Approval Phase Times by Number of Review Cycles for NDA/BLAs
- Total Approval Phase for Drugs with NDAs or BLAs Submitted FY1996-2006
- Comparator Drugs
- Distribution of Comparator Drugs by Sourcing Method
- Incidence of Comparator Drug Use in Clinical Trials
- Mean Number of Full-time Staff Dedicated to Obtaining Comparator Drugs and Co-Therapies
- Distribution of Comparator Drugs by Type
- Investigative Site Performance
- Site Initiation Timeline
- Site Initiation Timeline by TA
- First Patient-In Cycle Time
- First Patient-In Cycle Time Breakdown
- First Patient-In Cycle Time by TA
- First Patient-In Cycle Time Breakdown by TA
- Benchmark Cost Per Patient by Major TA
- Average Number of Patients Per Study for the Major Therapeutic Areas
- Median Number of Patients Per Phase Study
- Average Duration of Phase Studies
- Average Duration of Phase Studies
- Growth of Active Global Development Projects by Phase
- Top Perceived Challenges by Medical Device Executives
- Distribution of Protocol Procedures by Endpoint Type
CHAPTER THREE
DRUG DEVELOPMENT ECONOMICS

- Average Cost to Develop One New Approved Drug
- Total Estimated Global Spending on Select Contract R&D Services Markets
- Global R&D Spending
- R&D Spending
- Biopharmaceutical Company Investment in R&D
- Pharmaceutical R&D Expenditure
- Eroding Contribution from Launched Innovations
- Benchmark R&D Spend as a Percentage of Sales
- R&D Spending as a Percent of Sales by Sector
- Benchmark R&D Spending and Annual Growth
- Global R&D Spending by Clinical Trial Phase
- Global R&D Spending by Phase
- Global R&D Spend in Phase as Percent of Total
- Direct and Capitalized Cost of Developing a Single Drug
- Total Global Spending on Clinical Development
- Clinical Services Outsourcing
- Reported Percentage of Annual R&D Budget Spent on Outsourcing
- Growth in Global Phase I-III Clinical Trial Grant Spending
- Total Clinical Trial Grant Spending
- Mean Cost Per Patient by Phase
- Annual Growth in Per Patient Cost
- Mean Cost Per Patient by Therapeutic Area Across Phases I-III
- Screen Failure Costs as a Percentage of Total Cost per Patient
- Mean Per Patient Costs 2008-2011 Relative to North American Rates
- Average Number of Patient Payments by Annual Recruitment Volume
- Reported Time Required for Sites to Process One Payment
- Reported Number of Administrative Steps per Patient Payment
- Mean Patient Reimbursement Per Visit
- Mean Patient Reimbursement Per Visit by Therapeutic Area Across Phases II & III
- Industry Spend on KOLs
- Average Hourly Rates
- Clinical Trials Laboratory Services Market
- Comparing Annual Growth Rates
- Clinical Lab Test Market Segments, 2013
- Examples of Private Equity Participation in Study Conduct Market
- Examples of CROs Acquiring Investigative Sites/Site Networks
- Estimated 2013 Revenue of the Largest Investigative Sites
- Contract Services Adoption Rates in Drug Development
- Biotech Deals Involving Corporate Venture Capital Funds
- Profit Margins for Publicly-Traded CROs are Growing
- The Largest Global Drug Development Contract Service Providers
- Top 10 Medical Device Companies
CHAPTER THREE
DRUG DEVELOPMENT ECONOMICS

• Comparing R&D Spending
• The Largest Medical Device Market Segments
• Generic Share of Prescriptions Filled
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

• Drug Development Spending by Company Size
• The Largest Global Drug Development Contract Service Providers
• Clinical Trials Laboratory Services Market Revenue in U.S. billions
• Sponsor/CRO Improvement Areas
• 30 Years of Expanding Services and Outsourcing Models
• Total Global Market for Contract R&D Services
• Distribution of Contract Clinical Services Market Segments
• Clinical Services Outsourcing
• Penetration Rates
• Proportion of Top 30 Pharma Companies in at Least One FSP/Multi-FSP/Integrated Alliance
• Expected Impact from Strategic Outsourcing Relationships
• High Global Demand for CRO Services
• CROs Perceived to Have the Best Industry Reputation
• Leading CROs
• Top Rated CROs
• Average CRO Ratings by Region
• Average CRO Rating Across Attributes
• Comparing Site Ratings of Overall Relationship Quality with CROs
• Overall Ratings of CRO and Sponsor Performance by Relationship Category
• Site Ratings of Sponsor and CRO Relationship Attributes

• Site Ratings of Sponsor and CRO Study Conduct Support Attributes
• Number of Sponsor FTEs Assigned per 100 Dedicated CRO FTEs
• Sponsor Participation in Open Innovation Initiatives
• MSL Involvement with Investigational Products by Phase
• Distribution of MSL Time with Drug Product
• Average Number of Investigator-Initiated Clinical Trials per MSL
• Sponsor Plans for MSL Teams
• CRA-reported Days per Month Spent Visiting Sites, by Region
• Proportion of Study Monitors Performing 100% Source Verification, by Employer
• Incidence of Site Management Responsibilities Outsourced to CROs
• Site Management Responsibilities Outsourced by Company Size
• Incidence of Pre-study Visits Performed by Sponsors
• Average Number of Pages per Investigator Brochure
• Most Active Major CROs
• Major CRO Proclivity to Acquire Companies
• Comparing Major CRO M&A Activity Over Two Time Periods
• Projected FY 2013 Aggregate Revenue of the Top CROs by Ownership Structure
• Industry Acquisitions
• Industry Acquisitions
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

• Industry Acquisitions
• Industry Acquisitions
• Pharma Industry Job Cuts: U.S.
• Top Pharma Staffing Changes
• Pharma Executive Compensation
• Expected Impact from Strategic Outsourcing Relationships
• Risk-Based Monitoring
• Risk-Based Monitoring
• Management of Risk-Based Monitoring
• Management of Risk-Based Monitoring by Active Trial Volume
• Reported Risk-Based Monitoring Impact on Staff
• Preparation of Staff for Risk-Based Monitoring
• Investigative Site Landscape
• Examples of Private Equity Participation in the Study Conduct Market
• Examples of CROs Acquiring Investigative Sites/Site Networks
• Planned Staff Increases
• Comparing Site Infrastructure Levels
• Overall Study Grant Spending
• Investigative Site Financial Health
• 2013 Active & Newly Initiated Trial Volume

• Site Performance by Setting Type
• Study Start-Up
• Share of Principal Investigators World Wide
• Site Performance by Global Region
• Investigator Turnover Rates by Region
• Sponsor/CRO Payment Frequency
• Sponsor/CRO Payment Frequency
• Growth in Protocol Complexity
• 10-Year Overall Growth (2002-2012) in Total Procedures and Work Burden per Protocol by Phase
• High Volume of Complaints and Inspections against PIs
• Warning and GCP Letters to Clinical Investigators on the Decline
• Impact of Certification on Regulatory Compliance
• Can Site Performance be Predicted?
• Protocol Ready to Site Activation
• Comparing Part-time and Dedicated Site/Site Network Infrastructure Means
• Estimated 2013 Revenue of the Largest Investigative Sites
• Comparing Site Infrastructure Supporting Industry-Funded Clinical Trials
• Community Hospital Setting and U.S. Location
• Primary Perceived Challenges of Supporting Clinical Research Programs at Community Hospitals
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

• Primary Perceived Benefits of Supporting Clinical Research Programs at Community Hospitals
• More Than Half of Community Hospitals are Part of a Larger Health System
• Community-Hospital Planned Investment Areas to Grow Clinical Research Programs
• Growing Proportion of Global Community-based Investigators
• Part-time v. Dedicated Sites
• Segmentation of the Industry-sponsored Clinical Grants Market 2013
• Greatest Causes of Delays
• Global Distribution of 1572 Filings
• Active Unique Investigators Filing Form 1572s Worldwide
• No Change in Site Landscape Fragmentation
• The Global Investigative Site Landscape
• Unique Principal Investigators in North America Submitting at least one Form 1572
• Investigator Growth in North America v. Asia
• Unique Principal Investigators in Southeast Asia Submitting at least one Form 1572
• Unique Principal Investigators in South Asia Submitting at least one Form 1572
• Unique Principal Investigators in East Asia Submitting at least one Form 1572
• The Investigative Site Landscape in Western Europe
• Distribution of Industry-Funded Clinical Trials in the U.S.
• Proportion of Novice Investigators Conducting Clinical Trials
• Growing Proportion of Global Community-based Investigators
• Global Market Share of Active Clinical Trials by Investigative Site Setting
• The Increasing Proportion of Low Volume Investigators
• Rolling Change in Total Active Unique Investigators Filing Form 1572s
• Principal Investigator Disparities
• Industry Spend on KOLs
• Comparing Network Size
• Geographic Focus and Scope
• Largest Site Management Organizations in 2000
• Segmentation of the Industry-sponsored Clinical Grants Market 2013
• Number of Clinical Grants Awarded
• Rising Scope and Declining Size of Clinical Trials
• Average Clinical Trial Grant Size
• Growth in Clinical Grant Revenue by Investigative Site Type
• Top Investigative Site Operating Concerns
• Investigative Site Expenses as a Percentage of Study Grant Revenue
• Investigative Site Expenses and Profit
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

- Allocation of Clinical Trial Grant Expenses
- Site Operating Profit
- Hidden Cost Recovery
- Examples of Uncompensated Study Costs
- Screen Failure Costs as a Percentage of Total Cost per Patient
- Global Investigative Site Mean Revenue and Profitability
- Global Investigative Site Mean Revenue and Profitability
- Revenue and Profitability by Investigative Site Size
- Profile: Small Sites
- Profile: Mid-sized Sites
- Profile: Large Sites
- Site Perceptions of Profit per Study Grant
- Sponsor Payment Promptness
- Type of Accounting Method Used by Investigative Sites
- Wide Differences in Site Payable and Receivable Cycles
- Percentage of Clinical Research Revenue Owed That is Written off as Bad Debt in 2011
- Site Reported Cancellations
- Site Reported Recovery of Start-Up Costs Associated with Cancellations
- Economic Outlook by Years of Site Experience Conducting Clinical Trials
- Investigative Site Outlook 2011
- Perceived Economic Conditions 2012 compared to 2011
- Profit Expectations for 2012
- Perception of 2012 Economic Conditions Compared to 2011
- Investigative Site Plans to Hire Personnel in 2012
- Global Investigative Site Staffing Mean Number of Employees
- Distribution of Investigators by Site Type
- Investigative Site Personnel Size
- Total FTE Employees* per Investigative Site
- Mean Number of Employees by Staff Type
- Mean Number of Employees by Staff
- Part-time v. Dedicated Sites
- Average Hourly Rates
- Investigator Dropout Rates
- Investigator Dropout Rates
- Investigator Continuity and Decay Rates
- Volunteer Consent Rates
- Impact of Pre-study Visits
- Traditional and Non-Traditional Recruitment Tactics Used
- Typical Site Enrollment Performance
- Enrollment Achievement by All Sites in a Given Region
CHAPTER FOUR
CLINICAL RESEARCH PARTNERS

- Top Factors Most Often Causing Clinical Trial Delays
- Clinical Research Coordinators
- Years in Current Position Comparison to Previous Years
- Years Clinical Research Experience Comparison to Previous Years
- Years in Current Position by Years of Clinical Research Experience
- Clinical Research Coordinator Workload
- Clinical Research Coordinator Salaries
- Distribution of Full-Time Clinical Research Coordinators
- Distribution of Part-Time Clinical Research Coordinators
- Summary of Significant Differences For-Profit v. Not-for-Profit
- Highest Level of Education Completed (US)
- Highest Level of Education Completed (Non-US)
- Certification
- Certification - Organization
- Year Certified
- Ongoing Training
- Primary Training Sources
- PI and CRC Ratings of GCP Training
- Primary Payer of CE Credits

- Distribution of Full-Time Clinical Research Coordinators
- Distribution of Part-Time Clinical Research Coordinators
- Study Coordinators: Number of Years in Current Position
- Years in Clinical Research
- Study Coordinator Experience
- Length of Employment at Current Site
- Study Coordinator Employment Continuity
- Annual Full-Time CRC Turnover Rate
- Position CRCs Most Aspire to Advance Into
- Study Coordinator Base Salary
- Supplemental Income
- Average Supplemental Income
- Base Salary Increase Within Past Year
- Average % Base Salary Increase
- Number of Studies Personally Overseeing
- Number of Patients Personally Overseeing
- Number of Hours Work Per Week
- Responsibility Distribution
- Activity Distribution
- Change in Level of Responsibilities Over Past Year
CHAPTER FOUR
CLINICAL RESEARCH PARTNERS

• Change in CRC Responsibilities Over Past Year
• Perception: Is Salary Commensurate with Additional Workload?
• Most Common Obstacles in Completing Tasks
• Top Perceived CRC Career Benefits
• Top Perceived CRC Career Challenges
• Study Coordinator Distribution by Site Type
• PhRMA Personnel
• CRA Time Allocation by Region
• Regional Variation in CRA Quality-of-Life Assessments
• Patients/Study Volunteers
• Study Start-Up Cycle Time by Site Type
• Study Start-Up Cycle Time by Region
• Average Number of Volunteers Enrolled per Clinical Trial
• Losing Ineligible Volunteers
• Factors Contributing Most to Delays in Enrolling the First Patient
• Study Volunteer Attrition Rates
• 18-34-Year-Old Study Volunteers Require Special Attention
• Top Reasons Why Volunteers Choose to Participate
• Clinical Trial Information Seekers: Main Motivation
• Health Seekers’ Areas of Interest

• Profile of Six Million Clinical Trial Information Seekers
• Patients Seeking Clinical Trials Information
• Resources Used to Learn About Participating in Clinical Trials
• Methods Used to Search for Clinical Trials
• Participation in a Clinical Trial
• Consider Participating in a Clinical Trial Again
• How Many Studies Have You Participated In?
• Did You Seek Assistance in Deciding to Participate in a Clinical Trial?
• Major Factors Influencing Volunteers’ Decision to Participate in Trials
• Most Important Factors that Influence Your Decision to Participate in a Clinical Research Study?
• Factors Influencing the Decision to Participate
• Top Perceived Benefits and Risks
• Individual Involved in the Decision Making Process
• Sources for Clinical Research Information
• How Did You First Contact the Study Center?
• Preferred Method to Contact Research Center to Participate in a Clinical Trial
• Who did you Consult with Prior to Choosing to Participate in a Study?
• Evolving Public Perceptions
• Non-use of Social Media by Region
• Internet Resources Most Used by Patients for Clinical Trials Information
CHAPTER FOUR
CLINICAL RESEARCH PARTNERS

- Evaluation of the Informed Consent Process Before the Start of the Clinical Trial
- Did You Feel that You Understood the Benefits and Risks of Participating in a Clinical Trial?
- Study Participant Concerns
- Preference for Follow-up on Clinical Trials
- Most Frequent Illness Addressed
- Understanding Study Expectations
- Understanding StudyExpectations
- Understanding Study Expectations
- Reasons for Dropping Out
- How Would You Rate the Overall Quality of Care Received During the Study?
- Volunteer Ratings of Research Staff Who Conducted the Clinical Trial
- Study Volunteer Disparities in Clinical Research
- Patient Perceptions of Clinical Research Safety by Race and Ethnicity
- Patient Consent Rates when asked by Physician/PI, by Race and Ethnicity
- Patient Concentration by Physician Race and Ethnicity
- Patient-reported Top Sources of Clinical Trial Information
- 2011 Internet Usage Statistics
- Blogger Demographics
- Growth of Routine Usage of Social Networks by Adult Internet Users
- Social Media Website Usage
- Patient Organizations Funding Clinical Research
- Distribution of Medical Apps on Mobile Devices
- Patient Reported Use of Mobile Devices in Clinical Trials
- Where Sponsors Plan to Seek Input from Patient Panels
CHAPTER FIVE

CLINICAL RESEARCH PRACTICES

- Protocol Design
- Protocol Complexity and Execution Burden
- Complexity and Work Burden by Phase
- Impact on Clinical Trial Performance
- The Impact of Complexity on Study Performance
- Protocol Complexity Impact on Cycle Time
- Growth in Protocol Complexity and Work Burden by Phase
- How Important is Protocol Design to Your Decision to Participate in a Clinical Trial?
- Phase II and III Study Execution 2012
- Distribution of Protocol Procedures
- Distribution of Protocol Procedures by Endpoint Type
- Amendment Prevalence
- Amendment Prevalence by TA
- Avoiding Amendments
- Amendment Timing
- Procedure Support of Endpoints
- Distribution of Procedures by CSR/Analysis Plan Classifications
- Distribution of, and Total, Direct Cost per Classified Protocol Procedures
- Distribution and Cost of Procedures by Endpoint Classification and Phase
- Average Cycle Time from Pre-study Visit to Site Initiation
- 2013 Newly Initiated Trials by For-Profit vs. Not-for-Profit
- Relationship Management and Effectiveness
- Average 2011 Rating of Relationship Quality for a Typical Sponsor
- Sponsor Rating of Overall Relationship Quality
- Regional Comparison - Average Sponsor Ratings
- Average Sponsor Ratings by Site Type
- Average Sponsor Ratings by Years of Experience
- Company Ratings of Relationship Quality
- Company Ratings of Relationship Quality
- Frequency of Attributes in Top 3
- Essential Attributes to Study Success
- The Top Sponsors by Essential Attributes
- Evaluating Sponsor Performance
- Evaluating Sponsor Performance
- Comparing Performance Quality to Category Importance
- Comparing Attribute Importance to Sponsor Performance - Gaps
- Quality of Staff Professionalism
- Quality of Workstyle
- Quality of General Project Management
- Quality of Study Initiation Process
CHAPTER FIVE

CLINICAL RESEARCH PRACTICES

- Quality of Ongoing Study Conduct
- Quality of Grant Payment Process
- Average 2011 Relationship Quality Rating for the Typical CRO
- Benchmark Proportion of Sites Rating CRO Relationship Quality
- Regional Comparison of Average CRO Ratings
- Average CRO Ratings by Site Type
- Average CRO Ratings by Years of Experience
- Site Ratings by Experience and Setting
- Comparing Performance Quality to Category Importance
- Comparing Attribute Importance to CRO Performance - Gaps
- Quality of Staff Professionalism
- Quality of Workstyle
- Quality of General Project Management
- Quality of Study Initiation Process
- Quality of Ongoing Study Conduct
- Quality of Grant Payment Process
- Sponsors Engaging More Sites to Each Enroll Fewer Patients
- Investigative Site Enrollment Performance
- Comparing Start-up Performance by Site Type
- Comparing Enrollment Performance by Site Type
- Number of Countries in which Sponsors are Placing Clinical Trials
- Key Performance Metrics For Investigative Sites by Region
- Trends in Oncology Trial Protocol Complexity
- Days Spent On Site Each Month by Study Monitors
- Comparing Site Ratings of Overall Relationship Quality with CROs
- Sponsors Receiving Top Relationship Ratings from their Sites
- Site Assessment of Relationship Attribute Importance and of Sponsor Ability to Provide Them
- Gaps Between Relationship Attribute Importance and ‘Excellence’ Ratings of Sponsor Ability to Provide Them
- Individual Relationship Attributes Rated the Highest
- Individual Relationship Attributes Rated the Lowest
- Sites Rate Each Company’s Overall Reputation as a Sponsor of Clinical Research
- Tracking the Migration of Large Pharma into Integrated Alliances
- Comparing Market Capitalization and Revenue Multiples of Major Public CROs
- CRO Market Concentration
- CRO Market Consolidation Accelerating
- Lopsided CRO Landscape
- Comparing Incidence of Change Orders by Sponsor-CRO Relationship Type
- Perceived Actual CRO Performance Relative to Plan
CHAPTER FIVE

CLINICAL RESEARCH PRACTICES

- Perceived Contribution of Innovative Ideas from CROs
- Tracking the Potential for Conflicts of Interest
- Sponsor/CRO Payment Frequency
- Sponsor and CRO Payment Frequency
- 2013 Active & Newly Initiated Trial Volume
- 2013 Active Trial Volume by Site Type
- Greatest Causes of Delays
- 2013 Financials by Site Type
- 2013 Financials by Clinical Trial Volume
- Distribution of Study Budget Direct Costs by Procedure Type
- Investigator Turnover Rates by Region
- Planned Staff Increases
- Assessing the Impact of ACRP Certification
- Utilization of Monitoring Models
- Management of Risk-Based Monitoring by Active Trial Volume
- Risk-Based Monitoring Impact on Staff
- Management of Risk-Based Monitoring
- Familiarity With the Sunshine Act
- Anticipated Impact of the Sunshine Act on Investigator Willingness to Participate in Clinical Trials
- Patient Recruitment
- Number of Top 50 Giving Trial Results to Volunteers
- Moving to Patient-centered Practices
- The Patient Recruitment Challenge
- Probability of Successful Investigative Site Performance
- Preferred Patient Recruitment Methods
- Reasons Patients Seek Online Clinical Trials Information
- Patients’ Preferred Sources for Information About Clinical Research
- Patients’ Actual Reported Sources for Information About Clinical Research
- Top Site-Perceived Factors Contributing to Faster Cycle Times
- Factors Contributing Most to Delays in Enrolling the First Patient
- Factors That Most Often Cause Delays
- Factors That Could Best Prevent Future Delays
- Enrollment Delays
- Number of Certified Staff by Site Type
- CRA-reported Days per Month Spent Visiting Sites by Region
- Factors Determining the Frequency of On-site Monitoring Visits
- Total CRA-reported Workload per Month
- Allocation of Total CRA Hours per Month
- Perceived CRA Professionalism
CHAPTER FIVE
CLINICAL RESEARCH PRACTICES

• Enrollment Delays by Region
• Percent of Sites Extending Patient Enrollment Period
• Development Technology Solutions
• Company Reports on the Benefits of Cloud Computing Platforms
• Top Cloud Computing Pain Points for Managers
• Total Spending on Cloud Computing in the Global Healthcare Market
• CTMS Plans In Next Two Years
• EDC Solutions
• Estimated EHR Market Growth
• Hospital System Adoption of EHRs
• Practicing Physician Adoption of EHR Systems
• Barriers to Hospital System Adoption of EHRs
• Top Barriers to Practicing Physician Adoption of EHRs
• eCT Systems at Investigative Sites
• Top Reasons for Delay in Improving eCT Compatibility at Sites
• Preferred EDC Training Method
• Top Suggestions for Ways to Improve Sponsor/CRO Help Desk Support
• Proportion of Companies Performing 100% Source Verification
• Adverse Event Source Verification Practice
• Growth of Routine Usage of Social Networks by Adult Internet Users
• Social Media Website Usage
• Distribution of Medical Apps on Mobile Devices
• Reasons Sponsors are Using Mobile Health Apps
• Mobile Health Application Development
• Technology Use Among IRBs
• Top 10 Pharma Companies On Twitter
• Estimated size of the Big Data market
• Healthcare Investments in Big Data
• Number of Fortune 500 Companies Investing in Big Data Projects
CHAPTER SIX
THE GLOBAL PHARMACEUTICAL MARKET

- Global Pharmaceutical Sales
- Year-by-Year Growth in Global Pharmaceutical Sales
- Patent Expirations: Worldwide Sales At Risk
- Global Pharmaceutical Sales
- 2011 Global Pharmaceutical Sales by Region
- Distribution of Global Sales
- Forecasted Growth of Global Pharmaceutical Sales in Region
- Largest Therapeutic Areas by Global Pharmaceutical Sales
- Largest Therapeutic Areas by Global Pharmaceutical Sales
- Growth in Worldwide Prescription and OTC Sales by Therapeutic Area
- Growth in Worldwide Prescription and OTC Sales by Therapeutic Area
- Global Sales Contribution by Age of Drug
- 2011 U.S. Prescription Sales for the Top Therapeutic Classes
- 2011 U.S. Prescription Sales for the Next Therapeutic Classes
- Top 10 Prescription Products by Global Sales, 2013
- Next 10 Prescription Products by Global Sales, 2013
- Top Pharmaceutical Companies
- Next Top Pharmaceutical Companies
- Conventional and Biotech Drug Sales
- Generics and Branded Generics
- Top 10 Generic Companies 2012 Generic Revenues
- U.S. Prescriptions Filled with Generics
- Worldwide Prescription and OTC Sales
- Global Biosimilars
- Medicare Prescription Drug Program
- Select Medical Device Manufacturers
- Consolidation in the Medical Device Industry
- Expected Change During the Next Three Years in Medical Device Clinical Trials
- Operating Challenges for Medical Device Companies
- Recent IRB Mergers & Acquisitions
- Number of Commercial IRBs Operating in the U.S.
- Institutional Review Boards in Academic Settings
- Top Perceived Challenges by Medical Device Executives
CHAPTER SEVEN
DRUG DEVELOPMENT REGULATION

- IND and NDA Submissions and Approvals
- Number of IND Submissions
- Number of Commercial IND Submissions
- NME and NBE Submissions to CDER
- CDER NME and NBE Approvals
- Total NDA Submissions and Approvals
- Original NDA/BLA Submissions
- NDA Submissions by Filing Status
- BLA Submissions by Filing Status
- NDAs Approved in First Review Cycle
- NMEs/NBEs First-Cycle Review Outcomes
- NME Submissions by Filing Status
- Number of NDAs and NMEs Approved
- Approved NDAs and NMEs Receiving Priority Designations
- NMEs Approved with Postmarketing Requirements and/or REMs
- NME/BLA Approvals
- NDA Approvals
- New Biologic Approvals
- FDA Orphan Drug Approvals
- FDA Orphan Drug Designations
- FDA Orphan Drug Approvals and Designations
- Regulatory Review and Approval Cycle Time
- Cycle Time in Years from IND Approval to NDA Approval
- Mean NME Approvals Times
- Median Approval Times for Biotech Drugs and Biologics
- Mean EMA Processing Time for Human Medicinal Products
- FDA Inspection Results
- FDA, CDER Inspections of Sponsors and CROs
- Bioresearch Monitoring Inspections Overseen by FDAs CDER
- CDER Inspections of Clinical Investigators
- Foreign and Domestic Clinical Investigator Inspections Conducted by OSI
- Complaints Filed Against Investigators Annual Complaints Received by CDER
- Complaints Filed Against Investigative Sites as a Percentage of Active INDs
- OSI Warning and NIDPOE Letters
- 2012 OSI Inspection Results Percent of all inspections
- 2012 OSI Inspection Identified Clinical Investigator Deficiencies
- Investigator Deficiencies: Final Classification of OAI
- Site Audit Preparedness
- Warning Letters Issued to Principal Investigators
- FDA Inspection Results
CHAPTER SEVEN

DRUG DEVELOPMENT REGULATION

• Investigator Disqualifications
• Complaints Received, and Inspections Performed, by the FDA for Noncompliance and Fraud
• Distribution of Complaints against Investigators for Noncompliance and Fraud Percent of total complaints received
• Volume of Physician-filed INDs
• Investigator-Initiated Trials as a Proportion of Active INDs
• Tracking IND Submission

• Number of Commercial IRBs in the U.S.
• Comparing IRB Protocol Review Times
• Annual Reported Change in Workload and Resources Required
• Incidence and Level of Commercial IRB Use by Institutional IRBs
• Technology Use Among IRBs
• Evaluable Patients per NDA
• Average Number of Pages per Investigator Brochure